Pyxis Oncology Inc’s recent filing unveils that its CFO & COO Connealy Pamela Ann acquired Company’s shares for reported $0.17 million on Nov 26 ’24. In the deal valued at $1.96 per share,88,850 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 1,199,143 shares worth roughly $1.25 million.
William Blair downgraded its Pyxis Oncology Inc [PYXS] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Stifel began covering PYXS with “Buy” recommendation on August 08, 2024.
Price Performance Review of PYXS
On Tuesday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock fall -2.80% to $1.04. Over the last five days, the stock has lost -8.77%. Pyxis Oncology Inc shares have fallen nearly -33.33% since the year began. Nevertheless, the stocks have fallen -83.31% over the past one year. While a 52-week high of $6.18 was reached on 01/07/25, a 52-week low of $1.06 was recorded on 03/11/25. SMA at 50 days reached $1.4188, while 200 days put it at $2.8368.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 0.9883, which if violated will result in even more drops to 0.9367. On the upside, there is a resistance level at 1.0883. A further resistance level may holdings at 1.1367. The Relative Strength Index (RSI) on the 14-day chart is 28.52, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0800, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.90%. Stochastics %K at 14.83% indicates the stock is a buying.
The most recent change occurred on February 09, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
